Market Overview

According to fortune business insights, the global cell line development market size was valued at USD 6.79 billion in 2025. The market is projected to grow from USD 7.41 billion in 2026 to USD 16.36 billion by 2034, exhibiting a CAGR of 10.40% during the forecast period. North America dominated the cell line development market with a market share of 38.58% in 2025.

The analysis shows that top companies are investing more in advanced cell line platforms to meet the rising demand for biologics, biosimilars, and cell and gene therapies. The need for stable, high-performing cell lines to improve productivity, reduce development timelines, and ensure manufacturing consistency is driving growth. This trend indicates strong demand for cell line development solutions as a critical part of upstream bioprocessing.

Major Players Profiled in the Market Report:

• Thermo Fisher Scientific Inc. (U.S.)
• Lonza Group AG (Switzerland)
• Sartorius AG (Germany)
• WuXi Biologics (China)
• Merck KGaA (Germany)
• Danaher Corporation (U.S.)
• Samsung Biologics Co., Ltd. (South Korea)
• Catalent, Inc. (U.S.)
• KBI Biopharma, Inc. (U.S.)
• AGC Biologics (U.S.)

Segments

Outsourcing Trend to Propel Services Segment Growth

Based on offering, the market is divided into instruments, consumables, services, and software/platforms. The services segment holds the largest market share as many biopharma companies outsource cell line development to specialized CDMOs to reduce timelines, manage technical risk, and access advanced platforms.

Strong Use in Complex Biologics to Drive Mammalian Cell Lines Segment Expansion

By cell line type, the market is categorized into mammalian cell lines and non-mammalian cell lines. The mammalian cell lines segment is leading the market, as hosts like CHO and HEK293 are essential for producing complex biologics that require human-like protein modifications.

Core Role in Biologics Manufacturing to Dominate Bioproduction Segment